StockData

Halozyme Therapeutics vs Repligen

HALO and RGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HALO and RGEN compare

Halozyme Therapeutics and Repligen are about the same size, with market caps of $10.9B and $10.4B.

Halozyme Therapeutics grew revenue faster over the last twelve months (41.2% versus 13.8% for Repligen).

Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −1.5% at Repligen.

Halozyme Therapeutics scores higher on the StockData Score (13 against 7 for Repligen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHALORGEN
Size and price
Market cap$10.9B$10.4B
Share price$95.97$162.18
Change, 1 year37.0%6.4%
Change, 5 years184%−43.3%
Beta (5Y)0.821.36
Employees4232,000
StockData Score
Total score13 (better)7
Valuation score00
Growth score4 (better)3
Performance score5 (better)2
Health score4 (better)2
Dividend score00
Valuation
P/E28.3×–
P/S6.5× (better)12.9×
P/B75.9×5.0× (better)
EV/EBITDA21.0× (better)98.9×
P/FCF13.5× (better)97.1×
PEG1.34–
FCF yield7.4% (better)1.0%
Fair value$69.98$69.93
Margin of safety−37.1% (better)−132%
Growth
Revenue growth (TTM)41.2% (better)13.8%
Revenue growth, 5Y average39.2% (better)15.0%
Net income growth (TTM)−25.8% (better)−779%
EPS growth (TTM)−22.4%–
EPS growth, 5Y average23.0% (better)−5.0%
Profitability
Gross margin82.4% (better)53.5%
Operating margin35.9% (better)2.3%
Net margin24.9% (better)−1.5%
FCF margin48.5% (better)13.2%
Return on equity174% (better)−0.57%
Return on invested capital21.7% (better)0.71%
Financial health
Debt / equity14.95–
Net debt / EBITDA3.24–
Interest coverage29.4× (better)0.8×
Current ratio2.719.88 (better)
Altman Z-score4.458.41 (better)
Piotroski F-score57 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions109%104%
Held by insiders1.3%0.59%
Insider net buying, 12 months−$49.8M−$6.7M (better)
Superinvestors holding–2
Short interest, % of float12.2%11.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.